Displaying drugs 7551 - 7575 of 8271 in total
Apadenoson
Apadenoson is a selective A2a adenosine receptor agonist designed for use as a pharmacologic stress agent in cardiac perfusion imaging studies. It is developed by Bristol-Myers Squibb and is in phase II of clinical trials.
Investigational
Matched Description: … It is developed by Bristol-Myers Squibb and is in phase II of clinical trials. …
EP-2104R
EP-2104R is an imaging pharmaceutical under development for the detection of blood clots. It is the first targeted high-resolution technique designed to visualize blood clots directly. It is being developed by EPIX Pharmaceuticals, Inc.
Investigational
Matched Description: … EP-2104R is an imaging pharmaceutical under development for the detection of blood clots. …
ISIS 14803
ISIS 14803 is a 20-unit antisense phosphorothioate oligodeoxynucleotide that binds to hepatitis C virus (HCV) RNA at the translation initiation region of the internal ribosome entry site (IRES) and inhibits protein expression in cell culture.
Investigational
Matched Description: … oligodeoxynucleotide that binds to hepatitis C virus (HCV) RNA at the translation initiation region of …
Tiletamine
This drug is a dissociative anesthetic agent that falls under the drug category of NMDA receptor antagonists. Tiletamine is chemically similar to another dissociative anesthetic, ketamine. Tiletamine hydrochloride, the salt form, exists as odorless white crystals.
Vet approved
Matched Description: … This drug is a dissociative anesthetic agent that falls under the drug category of _NMDA receptor antagonists …
Garadacimab
Garadacimab is under investigation in clinical trial NCT04281524 (A Clinical Study to Test the Efficacy and Safety of CSL312 on Catheter-associated Blood Clot Formation in Subjects With Cancer Who Receive Chemotherapy Through a PICC Line).
Investigational
Matched Description: … under investigation in clinical trial NCT04281524 (A Clinical Study to Test the Efficacy and Safety of …
Edodekin alfa
Edodekin alfa is under investigation in clinical trial NCT01468896 (Cetuximab and Recombinant Interleukin-12 in Treating Patients With Squamous Cell Carcinoma of the Head and Neck That Is Recurrent, Metastatic, or Cannot Be Removed by Surgery).
Investigational
Matched Description: … NCT01468896 (Cetuximab and Recombinant Interleukin-12 in Treating Patients With Squamous Cell Carcinoma of …
Vonlerolizumab
Vonlerolizumab is under investigation in clinical trial NCT03029832 (A Study of MOXR0916 in Combination With Atezolizumab Versus Atezolizumab Alone in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma Who Are Ineligible for Cisplatin-based Therapy).
Investigational
Matched Description: … Vonlerolizumab is under investigation in clinical trial NCT03029832 (A Study of MOXR0916 in Combination …
AGS-16C3F
AGS 16C3F is an intravenously administered, anti-ectonucleotide pyrophosphatase/phosphodiesterase 3 (ENPP3) antibody-drug conjugate. AGS-16C3F is under investigation in clinical trial NCT02639182 (A Study of AGS-16C3F vs. Axitinib in Metastatic Renal Cell Carcinoma).
Investigational
Matched Description: … AGS-16C3F is under investigation in clinical trial NCT02639182 (A Study of AGS-16C3F vs. …
Tarcocimab tedromer
Tarcocimab tedromer is under investigation in clinical trial NCT06270836 (A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer Compared With Sham Treatment in Participants With Moderately Severe to Severe Non-proliferative Diabetic Retinopathy (NPDR)).
Investigational
Matched Description: … tedromer is under investigation in clinical trial NCT06270836 (A Study to Evaluate the Efficacy and Safety of …
CYT006-AngQb
CYT006-AngQb is a therapeutic vaccine in development for treatment of hypertension. It is designed to instruct the patient’s immune system to produce an antibody response against angiotensin II, a small peptide that causes blood vessels to narrow and results in increased blood pressure. It is a unique treatment modality that...
Investigational
Matched Description: … CYT006-AngQb is a therapeutic vaccine in development for treatment of hypertension. ... It is a unique treatment modality that aims to address the issue of patient compliance by offering convenient …
Lumiliximab
Lumiliximab is a chimeric monoclonal antibody which is used as an immunosuppressive drug. It is a primatized anti-CD23 macaque/human chimeric antibody that inhibits the production of the IgE antibody, for the potential treatment of allergic conditions. Lumiliximab was developed by IDEC Pharmaceuticals, which was acquired by Biogen. Clinical trials for...
Investigational
Matched Description: … antibody, for the potential treatment of allergic conditions. ... It is a primatized anti-CD23 macaque/human chimeric antibody that inhibits the production of the IgE …
Muraglitazar
Muraglitazar (Bristol-Myers Squibb/Merck) is a new agent under investigation for the treatment of patients with type 2 diabetes. It belongs to a novel class of drugs that target the peroxisome proliferator-activated receptors, both alpha and gamma subtypes. In addition to improvements in blood glucose and hemoglobin A1c (HbA1c), muraglitazar treatment...
Investigational
Matched Description: … Muraglitazar (Bristol-Myers Squibb/Merck) is a new agent under investigation for the treatment of patients ... It belongs to a novel class of drugs that target the peroxisome proliferator-activated receptors, both …
Allogeneic Cardiosphere-Derived Cells
Cardiosphere-derived cells (CDCs) are derived from human neonatal heart tissue with a distinct antigenic profile (CD105+, CD45-, and CD90low). They exert their effects by secreting exosomes: nanometer-sized, membrane-bound vesicles used for the purpose of cell-cell communication. CDCs target multiple cytokine pathways associated with poor outcomes (e.g. TNFa, IFN-y, IL-1B, and...
Investigational
Matched Description: … their effects by secreting exosomes: nanometer-sized, membrane-bound vesicles used for the purpose of ... The anti-inflammatory effects of CDC work through polarizing macrophages and restoring tissue function …
Droloxifene
Droloxifene, a derivative of the triphenylethylene drug tamoxifen, is a novel selective estrogen receptor modulator (SERM). Droloxifene also exhibits more rapid pharmacokinetics, reaching peak concentrations and being eliminated much more rapidly than tamoxifen. Its higher affinity to the estrogen receptor, higher anti-estrogenic to estrogenic ratio, more effective inhibition of cell...
Investigational
Matched Description: … Droloxifene, a derivative of the triphenylethylene drug tamoxifen, is a novel selective estrogen receptor ... affinity to the estrogen receptor, higher anti-estrogenic to estrogenic ratio, more effective inhibition of ... Droloxifene may also be a potentially useful agent for the treatment of postmenopausal osteoporosis because …
Vanillic acid
A flavoring agent. It is the intermediate product in the two-step bioconversion of ferulic acid to vanillin. (J Biotechnol 1996;50(2-3):107-13).
Experimental
Matched Description: … It is the intermediate product in the two-step bioconversion of ferulic acid to vanillin. …
Girentuximab
Girentuximab is a monoclonal chimeric (mouse/human) antibody directed against carbonic anhydrase IX, an antigen expressed in 95% of clear cell renal cell carcinomas (RCC).
Investigational
Matched Description: … chimeric (mouse/human) antibody directed against carbonic anhydrase IX, an antigen expressed in 95% of …
Aceneuramic acid
Aceneuramic acid has been used in trials studying the treatment of Distal Myopathy, Nonaka Type, Hereditary Inclusion Body Myopathy, and Distal Myopathy With Rimmed Vacuoles.
Investigational
Matched Description: … Aceneuramic acid has been used in trials studying the treatment of Distal Myopathy, Nonaka Type, Hereditary …
PZ-128
PZ-128 has been used in trials studying the prevention and treatment of Heart Diseases, Coronary Disease, Arteriosclerosis, Vascular Diseases, and Myocardial Ischemia, among others.
Investigational
Matched Description: … PZ-128 has been used in trials studying the prevention and treatment of Heart Diseases, Coronary Disease …
Varlilumab
Varlilumab has been used in trials studying the treatment of MELANOMA, Skin Ulcer, Burkett's Lymphoma, Mantle cell lymphoma, and Any T-cell Malignancy, among others.
Investigational
Matched Description: … Varlilumab has been used in trials studying the treatment of MELANOMA, Skin Ulcer, Burkett's Lymphoma …
Zuretinol acetate
Zuretinol acetate has been used in trials studying the treatment of Impaired Dark Adaptation, RP (Retinitis Pigmentosa), Retinitis Pigmentosa (RP), and LCA (Leber Congenital Amaurosis).
Investigational
Matched Description: … Zuretinol acetate has been used in trials studying the treatment of Impaired Dark Adaptation, RP (Retinitis …
Inclacumab
Inclacumab has been used in trials studying the treatment and prevention of Myocardial Infarction, Peripheral Arterial Disease (PAD), and Coronary Heart Disease, Graft Occlusion, Vascular.
Investigational
Matched Description: … Inclacumab has been used in trials studying the treatment and prevention of Myocardial Infarction, Peripheral …
AFN-1252
AFN-1252 has been used in trials studying the treatment of Cellulitis, Burn Infection, Wound Infection, Cutaneous Abscess, and Skin and Subcutaneous Tissue Bacterial Infections.
Investigational
Matched Description: … AFN-1252 has been used in trials studying the treatment of Cellulitis, Burn Infection, Wound Infection …
CP-547632
CP-547632 has been used in trials studying the treatment of Ovarian Cancer, Lung Neoplasms, Ovarian Neoplasms, Peritoneal Neoplasms, and Fallopian Tube Cancer, among others.
Investigational
Matched Description: … CP-547632 has been used in trials studying the treatment of Ovarian Cancer, Lung Neoplasms, Ovarian Neoplasms …
Foxy-5
Foxy-5 has been used in trials studying the treatment of Prostate Cancer, Colorectal Cancer, Metastatic Colon Cancer, Metastatic Breast Cancer, and Metastatic Prostate Cancer.
Investigational
Matched Description: … Foxy-5 has been used in trials studying the treatment of Prostate Cancer, Colorectal Cancer, Metastatic …
Hycanthone
Potentially toxic, but effective antischistosomal agent, it is a metabolite of LUCANTHONE. Hycanthone was approved by the FDA in 1975 but is no longer used.
Experimental
Matched Description: … Potentially toxic, but effective antischistosomal agent, it is a metabolite of LUCANTHONE. …
Displaying drugs 7551 - 7575 of 8271 in total